

1. Sahnane N, Gueli R, Tibiletti MG, Bernasconi B, Stefanoli M, Franzi F, Pinotti G, Capella C, **Furlan D**.
Pyrosequencing for EGFR mutation detection: diagnostic accuracy and clinical implications. *Diagn Mol Pathol*. 2013; 22(4):196-203. doi:10.1097/PDM.0b013e3182893f55.
2. **Furlan D**, Sahnane N, Mazzoni M, Pastorino R, Carnevali I, Stefanoli M, Ferretti A, Chiaravalli AM, La Rosa S, Capella C.
Diagnostic utility of MS-MLPA in DNA methylation profiling of adenocarcinomas and neuroendocrine carcinomas of the colon-rectum. *Virchows Arch*. 2013 Jan;462(1):47-56. doi: 10.1007/s00428-012-1348-2
3. La Rosa S, **Furlan D**, Franzi F, Battaglia P, Frattini M, Zanellato E, Marando A, Sahnane N, Turri-Zanoni M, Castelnuovo P, Capella C.
Mixed exocrine-neuroendocrine carcinoma of the nasal cavity: clinico-pathologic and molecular study of a case and review of the literature. *Head Neck Pathol*. 2013; 7:76-84. doi: 10.1007/s12105-012-0379-y.
4. La Rosa S, Marando A, **Furlan D**, Sahnane N, Capella C.
Colorectal poorly differentiated neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas: insights into the diagnostic immunophenotype, assessment of methylation profile, and search for prognostic markers. *Am J Surg Pathol*. 2012; 36:601-11. doi:10.1097/PAS.0b013e318242e21c.
5. **Furlan D**, Carnevali IW, Bernasconi B, Sahnane N, Milani K, Cerutti R, Bertolini V, Chiaravalli AM, Bertoni F, Kwee I, Pastorino R, Carlo C.
Hierarchical clustering analysis of pathologic and molecular data identifies prognostically and biologically distinct groups of colorectal carcinomas. *Mod Pathol*. 2011;24:126-37. doi: 10.1038/modpathol.2010.179.
6. Cerutti R, Sahnane N, Carnevali I, **Furlan D**, Tibiletti MG, Chiaravalli AM, Capella C.
Identification of the first case of germline duplication of BRCA1 exon 13 in an Italian family. *Fam Cancer*. 2010; 9:275-82. doi: 10.1007/s10689-009-9315-z.
7. Uccella S, Cerutti R, Placidi C, Marchet S, Carnevali I, Bernasconi B, Proserpio I, Pinotti G, Tibiletti MG, **Furlan D**, Capella C.
MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression. *J Clin Pathol*. 2009; 62:715-23. doi: 10.1136/jcp.2009.064741.
8. **Furlan D**, Sahnane N, Carnevali I, Cerutti R, Bertoni F, Kwee I, Uccella S, Bertolini V, Chiaravalli AM, Capella C.
Up-regulation of the hypoxia-inducible factor-1 transcriptional pathway in colorectal carcinomas. *Hum Pathol*. 2008; 39:1483-94. doi: 10.1016/j.humpath.2008.02.013.

9. **Furlan D**, Sahnane N, Carnevali I, Cerutti R, Uccella S, Bertolini V, Chiaravalli AM, Capella C.
Up-regulation and stabilization of HIF-1alpha in colorectal carcinomas.
Surg Oncol. 2007;16 Suppl 1:S25-7.
10. Sessa F, **Furlan D**, Zampatti C, Carnevali I, Franzi F, Capella C.
Prognostic factors for ampullary adenocarcinomas: tumor stage, tumor histology, tumor location, immunohistochemistry and microsatellite instability.
Virchows Arch. 2007;451(3):649-57.
11. **Furlan D**, Carnevali I, Marcomini B, Cerutti R, Dainese E, Capella C, Riva C.
The high frequency of *de novo* promoter methylation in synchronous primary endometrial and ovarian carcinomas.
Clin Cancer Res. 2006 1;12:3329-36.
12. Uccella S, Cerutti R, Vigetti D, **Furlan D**, Oldrini R, Carnevali I, Pelosi G, La Rosa S, Passi A, Capella C.
Histidine decarboxylase, DOPA decarboxylase, and vesicular monoamine transporter 2 expression in neuroendocrine tumors: immunohistochemical study and gene expression analysis.
J Histochem Cytochem. 2006; 54(8):863-75.
13. Chiaravalli AM, Feltri M, Bertolini V, Bagnoli E, **Furlan D**, Cerutti R, Novario R, Capella C.
Intratour T cells, their activation status and survival in gastric carcinomas characterised for microsatellite instability and Epstein-Barr virus infection.
Virchows Arch. 2006 Mar;448(3):344-53.
14. Agostini M, Tibiletti MG, Lucci-Cordisco E, Chiaravalli A, Morreau H, **Furlan D**, Boccuto L, Pucciarelli S, Capella C, Boiocchi M, Viel A.
Two PMS2 mutations in a Turcot syndrome family with small bowel cancers. Am J Gastroenterol. 2005 Aug;100(8):1886-91.
15. **Furlan D**, Bernasconi B, Uccella S, Cerutti R, Carnevali I, Capella C.
Allelotypes and fluorescence in situ hybridization profiles of poorly differentiated endocrine carcinomas of different sites.
Clin Cancer Res. 2005; 11(5):1765-75.
16. **Furlan D**, Cerutti R, Uccella S, La Rosa S, Rigoli E, Genasetti A, Capella C.
Different molecular profiles characterize well-differentiated endocrine tumors and poorly differentiated endocrine carcinomas of the gastroenteropancreatic tract.
Clin Cancer Res. 2004; 10(3):947-57.
17. **Furlan D**, Cerutti R, Genasetti A, Pelosi G, Uccella S, La Rosa S, Capella C.

Microallelotyping defines the monoclonal or the polyclonal origin of mixed and collision endocrine-exocrine tumors of the gut.
Lab Invest. 2003; 83(7):963-71.

18. Sessa F, **Furlan D**, Genasetti A, Billo P, Feltri M, Capella C.
Microsatellite instability and p53 expression in gallbladder carcinomas.
Diagn Mol Pathol. 2003; 12(2):96-102.
19. Suraweera N, Duval A, Reperant M, Vaury C, **Furlan D**, Leroy K, Seruca R, Iacopetta B, Hamelin R.
Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR.
Gastroenterology. 2002; 123(6):1804-11.
20. **Furlan D**, Casati B, Cerutti R, Facco C, Terracciano L, Capella C, Chiaravalli AM.
Genetic progression in sporadic endometrial and gastrointestinal cancers with high microsatellite instability.
J Pathol. 2002; 197(5):603-9.
21. Tibiletti MG, Bernasconi B, **Furlan D**, Bressan P, Cerutti R, Facco C, Franchi M, Riva C, Cinquetti R, Capella C, Taramelli R.
Chromosome 6 abnormalities in ovarian surface epithelial tumors of borderline malignancy suggest a genetic continuum in the progression model of ovarian neoplasms.
Clin Cancer Res. 2001; 7(11):3404-9.
22. Chiaravalli AM, Cornaggia M, **Furlan D**, Capella C, Fiocca R, Tagliabue G, Klersy C, Solcia E.
The role of histological investigation in prognostic evaluation of advanced gastric cancer. Analysis of histological structure and molecular changes compared with invasive pattern and stage.
Virchows Arch. 2001; 439(2):158-69.
23. La Rosa S, Sessa F, Colombo L, Tibiletti MG, **Furlan D**, Capella C.
Expression of acidic fibroblast growth factor (aFGF) and fibroblast growth factor receptor 4 (FGFR4) in breast fibroadenomas.
J Clin Pathol. 2001; 54(1):37-41.
24. Chiaravalli AM, **Furlan D**, Facco C, Tibiletti MG, Dionigi A, Casati B, Albarello L, Riva C, Capella C.
Immunohistochemical pattern of hMSH2/hMLH1 in familial and sporadic colorectal, gastric, endometrial and ovarian carcinomas with instability in microsatellite sequences.
Virchows Arch. 2001; 438(1):39-48.
25. Marozzi A, Manfredini E, Tibiletti MG, **Furlan D**, Villa N, Vegetti W, Crosignani PG, Ginelli E, Meneveri R, Dalprà L.

Molecular definition of Xq common-deleted region in patients affected by premature ovarian failure. *Hum Genet.* 2000; 107(4):304-11.

26. Tibiletti MG, Sessa F, Bernasconi B, Cerutti R, Broggi B, **Furlan D**, Acquati F, Bianchi M, Russo A, Capella C, Taramelli R.
A large 6q deletion is a common cytogenetic alteration in fibroadenomas, pre-malignant lesions, and carcinomas of the breast.
Clin Cancer Res. 2000; 6(4):1422-31.
27. **Furlan D**, Bertoni F, Cerutti R, Taborelli M, Pinotti G, Roggero E, Cavalli F, Bonato M, Zucca E, Capella C.
Microsatellite instability in gastric MALT lymphomas and other associated neoplasms.
Ann Oncol. 1999; 10(7):783-8.
28. Bertoni F, Codegoni AM, **Furlan D**, Tibiletti MG, Capella C, Brogginini M.
CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers.
Genes Chromosomes Cancer. 1999; 26(2):176-80.
29. Santarosa M, Dolcetti R, Magri MD, Crivellari D, Tibiletti MG, Gallo A, Tumolo S, Della Puppa L, **Furlan D**, Boiocchi M, Viel A.
BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy.
Int J Cancer. 1999; 83(1):5-9.
30. Tibiletti MG, **Furlan D**, Taborelli M, Facco C, Riva C, Franchi M, Cossu A, Trubia M, Taramelli R, Capella C.
Microsatellite instability in endometrial cancer: relation to histological subtypes.
Gynecol Oncol. 1999; 73(2):247-52.
31. **Furlan D**, Tibiletti MG, Taborelli M, Albarello L, Cornaggia M, Capella C.
The value of microsatellite instability in the detection of HNPCC families and of sporadic colorectal cancers with special biological features: an investigation on a series of 100 consecutive cases.
Ann Oncol. 1998; 9(8):901-6.
32. Tibiletti MG, Trubia M, Ponti E, Sessa L, Acquati F, **Furlan D**, Bernasconi B, Fichera M, Mihalich A, Ziegler A, Volz A, Facco C, Riva C, Cremonesi L, Ferrari M, Taramelli R.
Physical map of the D6S149-D6S193 region on chromosome 6Q27 and its involvement in benign surface epithelial ovarian tumours.
Oncogene. 1998; 16(12):1639-42.
33. Tibiletti MG, Bernasconi B, Taborelli M, **Furlan D**, Fabbri A, Franchi M, Taramelli R, Trubia M, Capella C.
Involvement of chromosome 6 in endometrial cancer.
Br J Cancer. 1997;75(12):1831-5.

34. Tibiletti MG, Bernasconi B, **Furlan D**, Riva C, Trubia M, Buraggi G, Franchi M, Bolis P, Mariani A, Frigerio L, Capella C, Taramelli R.
Early involvement of 6q in surface epithelial ovarian tumors.
Cancer Res. 1996; 56(19):4493-8.
35. Canevari S, **Furlan D**, Mossa A, Figini M.
Monoclonal antibodies by genetic engineering: novel reagents for in vivo diagnosis and therapy. Int J Biol Markers. 1993; 8(3):147-50.

N° 2 CONTRIBUTI IN VOLUME (CAPITOLO)

1. La Rosa S., **Furlan D.**, Sessa F., Capella C. (2010). The endocrine pancreas. In: Ricardo L.Lloyd . Endocrine pathology. Differential diagnosis and molecular advances, 2nd edition. p. 367-413, New York:Springer - Ricardo L.Lloyd Editor, ISBN: 9781441910684
2. S. La Rosa, **D. Furlan**, F. Sessa, Capella C. (2003). The endocrine pancreas. In: RICARDO V. LLOYD. Endocrine Pathology. Differential Diagnosis and Molecular Advances. p. 291-328, TOTOWA:Humana Press